Key result
T2D links to lower ANGPTL3 and ANGPTL8 but hyperlipidemia links to higher ANGPTL3 in hypertensive patients.
Why the study?
ANGPTL3, 4, and 8 regulate lipid and glucose metabolism, but their expression and association with comorbidities in hypertensive patients required investigation.
Cross-Sectional (n=87)
Circulating ANGPTL3 and ANGPTL8 levels are altered in hypertensive patients with common cardiovascular comorbidities like T2D and hyperlipidemia, suggesting a potential role in these conditions.
Associations of lower ANGPTL3/8 with T2D and higher ANGPTL3 with hyperlipidemia in hypertensives are hypothesis-generating; prospective studies needed before clinical consideration.
Background: ANGPTL3, 4 and 8 have been reported to be involved in the regulation of lipid and glucose metabolism. The aim of this study was to investigate the expression of ANGPTL3, 4, 8 in hypertensive patients with or without overweight/obesity, T2D, and hyperlipidemia, and the possible association between their expression and the status of the aforementioned comorbidities. Methods: Plasma levels of ANGPTL3, 4, and 8 in 87 hospitalized patients with hypertension were measured using ELISA kits. Associations between circulating ANGPTLs levels and the most common additional cardiovascular risk factors were assessed using multivariate linear regression analyses. Pearson's correlation analysis was used to examine the association between ANGPTLs and clinical parameters. Results: In the context of hypertension, (1) although not statistically significant, circulating ANGPTL3 levels were higher in the overweight/obese group than in the normal weight group; (2) circulating levels of ANGPTL3 and ANGPTL8 were significantly lower in patients with T2D than in non-diabetic patients; (3) circulating ANGPTL3 levels were significantly higher in the hyperlipidemic group than in the non-hyperlipidemic group. ANGPTL3 was associated with T2D and hyperlipidemia status, whereas ANGPTL8 was independently associated with T2D status. In addition, circulating ANGPTL3 levels were positively correlated with TC, TG, LDL-C, HCY, and ANGPTL8, and circulating ANGPTL4 levels were positively correlated with UACR and BNP. Conclusion: Changes in circulating ANGPTL3 and ANGPTL8 levels have been observed in hypertensive patients with the most common additional cardiovascular risk factors, suggesting a role in the common comorbidities of hypertension and cardiovascular disease. Hypertensive patients with overweight/obesity or hyperlipidemia may benefit from therapies targeting ANGPTL3.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) conducted a cross-sectional in Hypertension (n=87). Plasma levels of ANGPTL3, 4, and 8 vs. Patients without overweight/obesity, T2D, or hyperlipidemia was evaluated on Association between circulating ANGPTLs levels and cardiovascular risk factors. Plasma levels of ANGPTL3 and ANGPTL8 in 87 hypertensive patients were significantly lower in those with T2D, whereas ANGPTL3 levels were significantly higher in those with hyperlipidemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: